All In Biotech

Free tool

FAERS Monitor: Gleostine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017588 or its brand name (Gleostine, Lomustine). Reports on generic versions are filed under their own applications.

Reports

2,597

Serious

1,796

69% of reports

Hospitalization

553

Death reported

587

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death273
  • off label use254
  • nausea232
  • fatigue219
  • thrombocytopenia187
  • disease progression144
  • neutropenia134
  • drug ineffective126
  • platelet count decreased114
  • vomiting110
  • seizure92
  • headache87
  • product use in unapproved indication77
  • constipation73
  • malignant neoplasm progression73

Reports by year received

View as table
YearReports
20048
20053
20067
200711
200811
200921
201026
201116
201254
201330
201454
201573
201694
2017247
2018298
2019291
2020232
2021238
2022222
2023219
2024156
2025152
2026134

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,562 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
thrombocytopeniaSignal18713.611.82,172
disease progressionSignal1449.98.41,144
platelet count decreasedSignal1148.77.2769
neutropeniaSignal1348.06.8817
seizureSignal926.55.3421
malignant neoplasm progressionSignal735.84.6285
constipationSignal732.72.278
deathSignal2732.62.3271
product use in unapproved indicationSignal772.52.070
nauseaSignal2322.42.1190
off label useSignal2542.32.1204
fatigueSignal2192.32.0162
vomiting1101.91.647
headache871.10.91
drug ineffective1260.80.79

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.